GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Biologic Products Holdings Inc (NAS:CBPO) » Definitions » Current Deferred Revenue

China Biologic Products Holdings (China Biologic Products Holdings) Current Deferred Revenue : $0.0 Mil (As of Sep. 2020)


View and export this data going back to 2001. Start your Free Trial

What is China Biologic Products Holdings Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

China Biologic Products Holdings's current deferred revenue for the quarter that ended in Sep. 2020 was $0.0 Mil.

China Biologic Products Holdings Current Deferred Revenue Historical Data

The historical data trend for China Biologic Products Holdings's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Biologic Products Holdings Current Deferred Revenue Chart

China Biologic Products Holdings Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.93 3.98 2.43 9.10 7.63

China Biologic Products Holdings Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 7.63 - - -

China Biologic Products Holdings Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of China Biologic Products Holdings's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


China Biologic Products Holdings (China Biologic Products Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19 Chaoyang Park Road, 18th Floor, Jialong International Building, Chaoyang District, Beijing, CHN, 100125
China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.
Executives
Zhijing Cbpo Liu officer: Corporate Vice President 19 CHAOYANG PARK ROAD 18/F, JIALONG INTERNATIONAL BUILDING BEIJING F4 100125
Sean Shao director 21ST FLOOR, EVERBRIGHT BANK BUILDING, ZHUZILIN, FUTIAN DISTRICT, SHENZHEN, GUANGDONG F4 518040
David Gao director, officer: Chief Executive Officer C/ BEIJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Albert Yeung director C/O BEIJING MED-PHARM CORPORATION 600 WEST GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
David Hui Li director C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK NY 10017
Min Fang director UNIT 2206, BUND CENTER OFFICE TOWER NO. 222 YANAN ROAD (EAST) SHANGHAI F4 200002
Zhijun Tong director C/O BMP SUNSTONE CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Joseph Chow director 10110 SORRENTO VALLEY ROAD SUITE C SAN DIEGO CA 92121
Yungang Lu director 4TH FLOOR, ZHONGDIAN INFORMATION TOWER 6 ZHONGGUANCUN S. ST., HAIDIAN DIST. BEIJING F4 100086
Warburg Pincus Llc 10 percent owner 450 LEXINGTON AVENUE, NEW YORK NY 10017
Wp X Biologics Llc director, 10 percent owner C/O WARBURG PINCUS LLC 450 LEXINGTON AVENUE NEW YORK X1 10017
Warburg Pincus X Partners, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus Private Equity X, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X Gp L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus X, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017

China Biologic Products Holdings (China Biologic Products Holdings) Headlines